Amanta Healthcare Ltd Q3 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Q3 FY26 earnings call: what management guided on revenue, margins and order book.

Published 16 Jul 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹607 Cr

Revenue expected to reach approximately INR400 crores by March 2027, implying about 33% growth next year. Revenue is expected to grow roughly 33% in FY’27, reaching around INR400 crores, primarily driven by SteriPort expansion.

From Amanta Healthcare Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.

📊 Revenue & Sales Performance

→Revenue expected to reach approximately INR400 crores by March 2027, implying about 33% growth next year.
→SteriPort incremental revenue projected around INR120 crores post-expansion.
→SVP expansion to add roughly INR30 crores incremental revenue, commissioning expected by January 2027, though full value creation will take 1-2 years due to regulatory approvals and product ramp-up.
→20%+ CAGR growth rate anticipated over the next two years.
→Post-expansion, significant scale-up in production with output reaching full capacity quickly, with inventory normalization expected within 6-9 months.
→Overall combined incremental revenue potential of SteriPort and SVP lines is about INR150 crores.
→Growth supported by product mix improvement, capacity expansion, operating leverage, and cost efficiencies (e.g., INR9 crores annual savings from solar power plant).

📈 Profitability & Margins

→Revenue is expected to grow roughly 33% in FY’27, reaching around INR400 crores, primarily driven by SteriPort expansion.
→EBITDA is projected to be around INR105 crores after expansion, with additional contributions from SVP line ramp-up later.
→EBITDA margins are expected to improve slightly post-expansion due to operating leverage and cost efficiencies, including INR9 crores annual savings from solar captive power.
→Net Profit (PAT) showed an 8.1% YoY increase in Q3 and a 51% increase over 9 months; profits are expected to improve further with margin normalization and business scaling.
→Debt reduction target of INR35–40 crores per year will continue, supported by internal accruals balancing working capital needs.
→EPS will reflect weighted average capital post-IPO, with likely growth as profitability and revenues scale.
→SVP revenue and profitability ramp-up is expected over 1-2 years due to regulatory approvals and product development timelines.

See what Amanta Healthcare Ltd said on profitability & margins — free account, 30 seconds.

🏗️ Capital Expenditure Plans

→Ongoing expansion initiated prior to IPO, combining two phases into one, started in 2024.
→Manufacturing equipment and utilities are being installed; expected commissioning by mid-March 2026.
→Commercial production for SteriPort line anticipated by April 2026, with full ramp-up taking 6-9 months.
→Incremental SteriPort revenue expected around INR120 crores; combined with SVP line, total incremental revenue approximately INR150 crores.
→SVP expansion planned to commission by January 2027, focusing on inhalation solutions (respules), with a 1-2 year ramp-up for value addition and approvals.
→Capex funded through IPO proceeds; post-expansion, capex levels expected to significantly reduce.
→Strategic focus remains on internal accruals for future growth without raising further debt.
→Solar captive power project underway, leading to INR9 crores annual cost savings with additional debt raised for this.

💰 Fundraising & Capital Structure

→No new equity fundraising is planned; IPO proceeds of INR55–60 crores are already earmarked for capex and IPO expenses.
→Current debt stands around INR185–190 crores (including INR120 crores long-term and INR50 crores working capital) with plans to reduce to INR150 crores next year.
→Working capital cycle improvements and internal cash accruals are expected to cover additional working capital needs from expansion, avoiding incremental debt increase.
→Management aims to repay INR35–40 crores of debt annually using operational cash flows.
→Some additional debt (~INR30 crores) was raised for the solar project, offsetting repayments, but overall debt cost efficiency improves due to cheaper borrowing.
→No plans to raise expensive equity to repay cheaper debt, focusing instead on debt repayment via cash flows post-expansion.

See what Amanta Healthcare Ltd said on fundraising & capital structure — free account, 30 seconds.

📋 Order Book & Pipeline

The provided transcript from the document does not explicitly mention details about the current or expected order book or pending orders for Amanta Healthcare Limited. The discussion focuses primarily on: - Working capital and cash position - Debt repayment plans and current debt levels - Revenue and expansion projections, especially related to SteriPort and SVP product lines - Market presence and capacity utilization - Financial performance including EBITDA, PAT, and operational efficiencies There is no direct information on specific order book size or pending orders in the excerpts on page 20 or surrounding pages. For order book details, one may need to consult other sections of the full report or company disclosures not included here.

Key Metrics

How does Amanta Healthcare Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Amanta Healthcare Ltd

See full Pharmaceuticals & Biotechnology sector rankings

Price

₹196

Market Cap

₹607 Cr

P/E Ratio

39.6

Amanta Healthcare Ltd — Quarterly revenue & net profit

Revenue Net Profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹77 Cr, net profit ₹6 Cr.

Full financials →

What Amanta Healthcar's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

OneSource Specialty Pharma Ltd (Q3 FY26)
OneSource Specialty Pharma is aggressively investing in capacity expansion with over INR 700 crores (approximately $100 million) planned for flagship site…
Mankind Pharma Ltd (Q3 FY26)
Overall domestic prescription business growth for Q3 was 9%+ and 8.2% for 9 months (excluding OTC), indicating steady growth. Key concall takeaways from…
Gland Pharma (Q3 FY26)
Investments of INR 2,000 crores over next 5 years, including Brownfield expansions, BFS lines, and ophthalmic lines, to enhance capacity and drive volume/value…
Shilpa Medicare (Q3 FY26)
Formulation business growing robustly, with 104% quarter-on-quarter growth excluding licensing income. Key concall takeaways from Shilpa Medicare's Q3 FY26…

Compare:vs Sun Pharmaceutical Industries Ltd vs Divi's Lab.vs Torrent Pharma.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Amanta Healthcare Ltd Q3 FY26 results?

What is Amanta Healthcare Ltd share price analysis?

Amanta Healthcare Ltd currently shows a neutral. The stock trades at a P/E of 39.6 with a market cap of ₹607 Cr. Investors should review the full earnings analysis for detailed insights.

Is Amanta Healthcare Ltd planning capital expenditure?

Ongoing expansion initiated prior to IPO, combining two phases into one, started in 2024.

Keep Amanta Healthcare Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.